定义阿达木单抗的治疗范围并预测银屑病应答:一项多中心前瞻性观察性队列研究
该多中心前瞻性观察性队列纳入544例接受阿达木单抗单药治疗的银屑病患者,建立个体化应答概率模型。最低有效药物水平3.2 μg/ml可区分应答者与非应答者,估计PASI75概率为65%(95%CI=60-71);7 μg/ml时PASI75概率为81%(95%CI=76-86),超过7 μg/ml后药物水平/应答曲线进入平台期。药物水平可预测6个月后的应答,且为决定治疗应答的最重要因素。
要点
- 最低有效阿达木单抗水平3.2 μg/ml可区分PASI75应答者与非应答者。
- 7 μg/ml时PASI75概率为81%(95%CI=76-86),超过7 μg/ml后曲线进入平台期。
- 药物水平可预测6个月后的应答,无论早期采样或稳态采样。
核心结论
- 血清药物水平是决定银屑病治疗应答的最重要因素。
- 该真实世界研究支持主动监测阿达木单抗水平以指导治疗策略。
研究设计与样本
- 多中心(n=60)前瞻性观察性队列,纳入544例接受阿达木单抗单药治疗且第一年内至少有一次血清样本和PASI评分的银屑病患者。
主要发现
- 最低有效药物水平3.2 μg/ml可区分应答者与非应答者,估计PASI75概率为65%(95%CI=60-71)。
- 7 μg/ml时PASI75概率为81%(95%CI=76-86),超过7 μg/ml后药物水平/应答曲线进入平台期。
- 药物水平可预测6个月后的应答,无论早期采样或稳态采样。
关键数值与推荐
- 最低有效药物水平3.2 μg/ml,估计PASI75概率65%(95%CI=60-71)。
- 7 μg/ml时PASI75概率81%(95%CI=76-86),超过7 μg/ml后曲线进入平台期。
临床怎么用
- 该真实世界研究支持主动测量阿达木单抗水平以指导银屑病治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologics have transformed management of inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by circulating drug levels has been proposed. We aimed to determine the real-world clinical utility of therapeutic drug monitoring in psoriasis. Within a multicenter (n = 60) prospective observational cohort, 544 psoriasis patients were included who were receiving adalimumab monotherapy and had at least one serum sample and Psoriasis Area and Severity Index (PASI) score available within the first year. We present models giving individualized probabilities of response for any given drug level: a minimally effective drug level of 3.2 μg/ml discriminates responders (PASI75 indicates 75% improvement in baseline PASI) from nonresponders, and gives an estimated PASI75 probability of 65% (95% confidence interval = 60-71). At 7 μg/ml, PASI75 probability is 81% (95% CI = 76-86); beyond 7 μg/ml, the drug level/response curve plateaus. Crucially, drug levels are predictive of response 6 months later, whether sampled early or at steady state. We confirm serum drug level to be the most important factor determining treatment response, highlighting the need to take drug levels into account when searching for biomarkers of response. This real-world study with pragmatic drug level sampling provides evidence to support the proactive measurement of adalimumab levels in psoriasis to direct treatment strategy, and is relevant to other inflammatory diseases.
引用
- Wilkinson N, Tsakok T, Dand N, et al. Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. J Invest Dermatol. 2018. PMID: 30130616. doi:10.1016/j.jid.2018.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。